PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference ISPT-1004(P	FOR FURTHER ACTION	see Notific (Form PCT below.	ation of Transmittal of International Search Report (/ISA/220) as well as, where applicable, item 5		
International application No. PCT/US03/18923	International filing date (day/mon 17 June 2003 (17.06.2003)		(Earliest) Priority Date (day/month/year) 17 June 2002 (17.06.2002)		
Applicant ISIS PHARMACEUTICALS, INC.					
This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau. This international search report consists of a total of					
1. Basis of the Report a. With regard to the language, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.					
the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).					
b. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of the sequence listing:					
contained in the international application in written form.					
filed together with the international application in computer readable form.					
furnished subsequently to this Authority in written form.					
furnished subsequently to th	furnished subsequently to this Authority in computer readable form.				
the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.					
the statement that the inform	the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.				
2. Certain claims were found	Certain claims were found unsearchable (See Box I).				
	Unity of invention is lacking (See Box II).				
4. With regard to the title,			•		
the text is approved as subm			· ·		
the text has been established	by this Authority to read as follow	S:			
	•				
5. With regard to the abstract,					
	the text is approved as submitted by the applicant. the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant				
the text has been established may, within one month from Authority.	, according to Rule 38.2(b), by this the date of mailing of this internati	Authority onal search	as it appears in Box III. The applicant report, submit comments to this		
6. The figure of the drawings to be published with the abstract is Figure No.					
as suggested by the applicant	·		None of the figures		
because the applicant failed t	because the applicant failed to suggest a figure.				
because this figure better cha	because this figure better characterizes the invention.				

Form PCT/ISA/210 (first sheet) (July 1998)

INTERNATIONAL SEARCH REPORT

nternational application No.

PCT/US03/18923

A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : C07H 21/04; C12N 5/00, 5/02; A61K 31/70; A01N 43/04 US CL : 536/24.5; 435/325, 375; 514/44					
According to International Patent Classification (IPC) or to both national classification and IPC					
B. FIELDS SEARCHED					
Minimum documentation searched (classification system followed by classification symbols) U.S.: 536/24.5; 435/325, 375; 514/44					
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched					
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Continuation Sheet					
C. DOC	C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category.*	Citation of document, with indication, where a	ppropriate, of the relevant passages Relevant to claim No.			
Y	US 6,114,517 (MONIA et al) 05 September 2000 (05.09.2000), see entire document. 1-20			
Y	US 20030027137 (CHEN et al) February 6 2003 (C	6.02.2003), see entire document. 1-20			
	·				
		*			
	+	_			
		.0			
	+ n				
	1				
Further documents are listed in the continuation of Box C. See patent family annex.					
	Special categories of cited documents:	"T" later document published after the international filing date or			
"A" document	it defining the general state of the art which is not considered to nicular relevance	priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention			
"E" earlier a	oplication or patent published on or after the international filing	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone			
"L" documen to establ (as speci	it which may throw doubts on priority claim(s) or which is cited ish the publication date of another citation or other special reason fied)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art			
"O" documen	t referring to an oral disclosure, use, exhibition or other means	-& document member of the same patent family			
"P" documen	t published prior to the international filing date but later than the				
Date of the actual completion of the international search Date of mailing of the international search report					
16 October 2004 (16.10.2004) U3 DEC 2004					
Name and mailing address of the ISA/US		Authorized officer / Lula () a () () ()			
Mail Stop PCT, Aun. ISA/US Commissioner for Patents		Janet L. Epps-Førd, Ph.D.			
P.C	D. Box 1450	Telephone No. 571-272-0547			
Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230					



Continuation of B. FIELDS SEARCHED Item 3:
CAplus, Medline, Biosis, USPatfull, Pctfull, Derwent, EPO, JPO
search terms: SMRT, silencing mediator for retinoid and thyroid hormone action, Nuclear receptor co-repressor 2, NCoR2, TRAC-1,
CTG26, TNRC14, and SMRTe.

NOTES TO FORM PCT/ISA/220 (continued)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

- 1. [Where originally there were 48 claims and after amendment of some claims there are 51]: "Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
- [Where originally there were 15 claims and after amendment of all claims there are 11]: "Claims I to 15 replaced by amended claims I to II."
- 3. [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:
 "Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or
 "Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
- 4. [Where various kinds of amendments are made]: "Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

"Statement under Article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

It must be in the language in which the international application is to be published.

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments and any accompanying statement, under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the time of filing the amendments (and any statement) with the International Bureau, also file with the International Preliminary Examining Authority a copy of such amendments (and of any statement) and, where required, a translation of such amendments for the procedure before that Authority (see Rules 55.3(a) and 62.2, first sentence). For further information, see the Notes to the demand form (PCT/IPEA/401).

Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see the PCT Applicant's Guide, Volume II.